Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 331 AL 345

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, Dowsett SA, Pontecorvo MJ, Dean RA, Demattos R.

Alzheimers Dement. 2016 Feb;12(2):110-120. doi: 10.1016/j.jalz.2015.06.1893. Epub 2015 Aug 1.

Alzheimer's disease lymphocytes: potential for biomarkers?

Wojda U.

Biomark Med. 2016;10(1):1-4. doi: 10.2217/bmm.15.79. Epub 2015 Dec 7.

Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies

Kamat PK, Kalani A, Rai S, Swarnkar S, Tota S, Nath C, Tyagi N.

Mol Neurobiol. 2016 Jan;53(1):648-661. doi: 10.1007/s12035-014-9053-6. Epub 2014 Dec 17.

Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease

Ji C, Xue GF, Li G, Li D, Hölscher C.

Rev Neurosci. 2016 Jan;27(1):61-70. doi: 10.1515/revneuro-2015-0021.

miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease

Mushtaq G, Greig NH, Anwar F, Zamzami MA, Choudhry H, Shaik MM, Tamargo IA, Kamal MA.

Med Chem. 2016;12(3):217-25. doi: 10.2174/1573406411666151030112140.

Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia

Szeto JY, Lewis SJ.

Curr Neuropharmacol. 2016;14(4):326-38. doi: 10.2174/1570159x14666151208112754.

Structural variants can be more informative for disease diagnostics, prognostics and translation than current SNP mapping and exon sequencing

Roses AD, Akkari PA, Chiba-Falek O, Lutz MW, Gottschalk WK, Saunders AM, Saul B, Sundseth S, Burns D.

Expert Opin Drug Metab Toxicol. 2016;12(2):135-47. doi: 10.1517/17425255.2016.1133586. Epub 2016 Feb 2.

Neuroprotective Effects of Fisetin in Alzheimer's and Parkinson's Diseases: From Chemistry to Medicine

Nabavi SF, Braidy N, Habtemariam S, Sureda A, Manayi A, Nabavi SM.

Curr Top Med Chem. 2016;16(17):1910-5. doi: 10.2174/1568026616666160204121725.

Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases

Irwin MH, Moos WH, Faller DV, Steliou K, Pinkert CA.

Drug Dev Res. 2016 May;77(3):109-23. doi: 10.1002/ddr.21294. Epub 2016 Feb 21.

Clinical drug research in chronic central neurodegenerative disorders

Müller T, Foley P.

Expert Rev Neurother. 2016 May;16(5):497-504. doi: 10.1586/14737175.2016.1163220. Epub 2016 Mar 21.

Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches

Salahuddin P, Fatima MT, Abdelhameed AS, Nusrat S, Khan RH.

Eur J Med Chem. 2016 May 23;114:41-58. doi: 10.1016/j.ejmech.2016.02.065. Epub 2016 Mar 2.

Omega-3 fatty acids for the treatment of dementia

Burckhardt M, Herke M, Wustmann T, Watzke S, Langer G, Fink A.

Cochrane Database Syst Rev. 2016 Apr 11;4(4):CD009002. doi: 10.1002/14651858.CD009002.pub3.

Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases

Hernando S, Gartziandia O, Herran E, Pedraz JL, Igartua M, Hernandez RM.

Nanomedicine (Lond). 2016 May;11(10):1267-85. doi: 10.2217/nnm-2016-0019. Epub 2016 Apr 14.

Altered NR4A Subfamily Gene Expression Level in Peripheral Blood of Parkinson's and Alzheimer's Disease Patients

Montarolo F, Perga S, Martire S, Navone DN, Marchet A, Leotta D, Bertolotto A.

Neurotox Res. 2016 Oct;30(3):338-44. doi: 10.1007/s12640-016-9626-4. Epub 2016 May 9.

Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)

Singh NA, Mandal AK, Khan ZA.

Nutr J. 2016 Jun 7;15(1):60. doi: 10.1186/s12937-016-0179-4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias